Drug Profile
DISC gene delivery - Xenova
Latest Information Update: 17 Jan 2005
Price :
$50
*
At a glance
- Originator Xenova Group
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malignant melanoma; Parkinsonian disorders
Most Recent Events
- 17 Jan 2005 DISC HSV and DISC GM CSF have been licensed to Oxxon Therapeutics Worldwide
- 28 Jul 2004 Discontinued - Preclinical for Malignant melanoma in United Kingdom (unspecified route)
- 15 Sep 2001 Discontinued - Preclinical for Parkinsonism in United Kingdom (unspecified route)